Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Tri-Mili
Overview
What is Tri-Mili?
Tri-Mili is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).
Each active white tablet contains 0.180 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.
Each active light blue tablet contains 0.215 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.
Each active dark blue tablet contains 0.250 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.
Each green tablet contains only inert ingredients, as follows: anhydrous lactose, FD&C Blue No. 2 aluminum lake, ferric oxide yellow, magnesium stearate, microcrystalline cellulose, and povidone.
What does Tri-Mili look like?
What are the available doses of Tri-Mili?
Tri-Mili consists of 28 round, biconvex tablets in the following order ():
What should I talk to my health care provider before I take Tri-Mili?
Nursing mothers: Not recommended; can decrease milk production. ()
How should I use Tri-Mili?
Tri-Mili tablets are indicated for use by females of reproductive potential to prevent pregnancy .
Tri-Mili is available in blister pack . Tri-Mili may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.
What interacts with Tri-Mili?
Sorry No Records found
What are the warnings of Tri-Mili?
Sorry No Records found
What are the precautions of Tri-Mili?
Sorry No Records found
What are the side effects of Tri-Mili?
Sorry No records found
What should I look out for while using Tri-Mili?
Do not prescribe Tri-Mili to women who are known to have the following conditions:
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke
What might happen if I take too much Tri-Mili?
There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
How should I store and handle Tri-Mili?
TREMFYA is sterile and preservative-free. Discard any unused portion.Keep out of reach of children.TREMFYA is sterile and preservative-free. Discard any unused portion.Keep out of reach of children.Product: 50090-1970Product: 50090-2212NDC: 50090-2212-0 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 50090-2212-1 90 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 50090-1970Product: 50090-2212NDC: 50090-2212-0 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 50090-2212-1 90 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 50090-1970Product: 50090-2212NDC: 50090-2212-0 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 50090-2212-1 90 CAPSULE, DELAYED RELEASE in a BOTTLEProduct: 50090-1970Product: 50090-2212NDC: 50090-2212-0 30 CAPSULE, DELAYED RELEASE in a BOTTLENDC: 50090-2212-1 90 CAPSULE, DELAYED RELEASE in a BOTTLE
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of ethinyl estradiol and norgestimate increases sex hormone-binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established.
Non-Clinical Toxicology
Do not prescribe Tri-Mili to women who are known to have the following conditions:Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke
Warfarin and other Oral Anticoagulants
Lithium
In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication.
Busulfan
Drugs that Inhibit CYP450 Enzymes
Drugs that Induce CYP450 Enzymes
T
h
r
o
m
b
oe
m
b
ol
ic Disorders and Other Vascular Problems:
L
i
ver
d
isease:
H
igh blood pressure:
Carbohydrate and lipid metabolic effects:
Headache:
Bleeding Irregularities and Amenorrhea:
The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:
Adverse reactions commonly reported by COC users are:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).